SISU Saw Palmetto Complex
Natural health product licensed in Canada
- Other names
- Saw Palmetto Complex, Saw Palmetto Plus
- Licence holder
- SISU
- NPN or DIN-HM
- 80033618
- Status
- Inactive licence
- Licence date
- 13 July 2012
- Revision date
- 4 May 2016
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Cucurbita pepo Source : Graine(s) Extraction ratio : 5:1 Dry plant equivalent : 250 mg | 50 mg | Not calculated |
| Serenoa repens Source : Fruit Extraction ratio : 4:1 Dry plant equivalent : 500 mg Potency : 25 % Fatty acids | 125 mg | Not calculated |
Non-medicinal ingredients
Dioxyde de silicium, Gélatine, Maltodextrine, Cellulose microcristalline, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe masculin | Not specified | 3 Capsule | 2 Tous les jours |
Uses authorised in Canada
Used in Herbal Medicine to help reduce difficulty in urination associated with the early stages of benign prostatic hyperplasia (BPH).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not take this product with any substances that cause acidic urine.
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use to exclude a diagnosis of prostate cancer. Discontinue use if you experience nausea or gastrointestinal discomfort.
Source
Official Health Canada record, licence 80033618
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2016. Photograph the packaging to check whether it has changed. Photograph the packaging